Ocular Surgery News

12/01/2025

📢AAPOS “believes there is a strong case for approving” dilute atropine formulations following the FDA’s recent decision not to approve SYD-101 for slowing pediatric myopia.

The American Association for Pediatric Ophthalmology and Strabismus issued a statement on Tuesday endorsing a “strong case” for approving an atropine formulation for myopia, in response to the FDA’s recent nonapproval of SYD-101.The AAPOS Myopia Task Force stated that the lack of a...

12/01/2025

🔬 Are Biosimilars Safe and Effective? Here’s What the Data Says

Before a biosimilar hits the market, it must prove through head-to-head studies that switching from the original biologic brings no difference in safety or effectiveness.

Yet, concerns persist.
📊 36% of rheumatologists still cite efficacy worries as a key reason they hesitate to prescribe them.

But the evidence is clear: biosimilars are well-studied, safe, and effective for both new and existing patients though ongoing monitoring remains essential.

Full breakdown inside Biosimilars: A Healio® Guide for Clinicians: https://bit.ly/4ltP5vx

11/30/2025

❗Q&A❗

Onboarding new employees takes time practices often do not have.

Alchemy Vision has tripled the number of eye care practices they service with digital training programs this year and hopes to reach 1,000 practices over the next 3 years.

Getting new employees ready to do their jobs can be a big undertaking for an eye care practice, no matter its size.

11/29/2025

A 42-year-old patient presents with:

Difficulty ambulating.
Fatigue.
Weight loss.
Worsening near .

Can you crack the case? 👀🤔 Read more on Healio:

A 42-year-old man presented to the emergency department with complaints of difficulty ambulating, fatigue, unintentional weight loss and progressively worsening near vision.His medical history was notable only for Bell’s palsy. He denied any surgical history and reported no current medication...

11/29/2025

On the move? 🚗 So are we. CME made easy, anywhere.

Tap In: https://bit.ly/47D8Rj7

11/28/2025

🕒 Short on time? Catch up quickly with expert pearls from ARVO & RWC on the latest retinal therapies.

Earn Credits Now: https://bit.ly/4ofeN9u

11/27/2025

🗨️“AAPOS believes there is a strong case for approving pharmaceutical formulations of dilute atropine, such as SYD-101, that may offer improved efficacy, better tolerability, more consistent delivery and increased access.”

The American Association for Pediatric Ophthalmology and Strabismus issued a statement on Tuesday endorsing a “strong case” for approving an atropine formulation for myopia, in response to the FDA’s recent nonapproval of SYD-101.The AAPOS Myopia Task Force stated that the lack of a...

11/26/2025

Lamivudine, an antiviral drug typically used for the treatment of , improved in patients with DME.

At about $20 per month, the drug could provide a less expensive and less invasive option for DME, according to a study.

More on Healio:

An oral HIV drug helped patients with center-involved diabetic macular edema achieve improvements in visual acuity, according to a study in Med.

11/26/2025

🚨The FDA’s decision not to approve SYD-101 for pediatric myopia “has important implications for pediatric eye care, myopia control research and ongoing unmet clinical needs,” said .

https://www.healio.com/news/ophthalmology/20251126/aapos-fdas-nonapproval-of-syd101-has-important-implications-for-pediatric-eye-care

The American Association for Pediatric Ophthalmology and Strabismus issued a statement on Tuesday endorsing a “strong case” for approving an atropine formulation for myopia, in response to the FDA’s recent nonapproval of SYD-101.The AAPOS Myopia Task Force stated that the lack of a...

11/26/2025

From :

Clinicians should consider patient motivation as well as clinical factors when thinking about starting a patient on medical therapy for .

Read more on Healio.👇

https://www.healio.com/news/ophthalmology/20251125/consider-progression-risk-patient-motivation-when-deciding-to-start-ga-therapy

OSN New York and Retina Meetings

NEW YORK — Patients need to be motivated before beginning therapy for geographic atrophy, according to a speaker at OSN New York Retina.

11/25/2025

❗Hovanesian InSight is back❗

Overcoming the challenges of implementing new /digital-based tools into practices will increase workplace satisfaction, according to Dr. John Hovanesian.

More on Healio:

https://www.healio.com/news/ophthalmology/20251124/blog-how-to-implement-a-new-digital-technology

Harvard Eye Associates

AI-based and other digital solutions are beginning to change the way we practice medicine, as I discussed in a recent blog.

11/25/2025

📊 The data is in—do your beliefs match the evidence? Take the facts vs. myths challenge and refine your approach to durable anti-VEGF therapy.

Start Earning Your Credits: https://bit.ly/47rQtLr